Oramed Pharmaceuticals (NSDQ:ORMP) said today that the FDA scheduled an end-of-phase II meeting with the Jerusalem-based company for August 31. Oramed is developing an oral insulin capsule for the treatment of Type II diabetes. The company’s Phase IIb trial met primary and secondary endpoints, since the insulin capsule lowered patients’ blood sugar relative to a placebo. […]
oramedpharmaceuticals
Oramed to dual-list on Tel Aviv exchange
Oramed Pharmaceuticals (NSDQ:ORMP) said today that it won approval from the Israel Securities Authority to dual-list its common stock on the Tel Aviv Stock Exchange. Stock in the Jerusalem-based company is slated to begin trading on the TASE on July 12 under the symbol ‘ORMP’. Get the full story at our sister site, Drug Delivery […]